NATCOPHARM · Natco Pharma Limited · Financials
Volume · Nov 13
159.56K
Avg daily vol (14 sessions)
55.3K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.
Revenue
40.78B
-7.9%
FY2026
Net Income
14.19B
-24.8%
FY2026
Operating Cash Flow
17.68B
+4.2%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| INR | 30.89B | 40.78B | 44.3B | 39.99B | 27.07B | 19.45B | 20.52B | 19.15B | 20.95B | 22.02B |
| INR | 1.93B | 2.07B | 2.35B | 1.87B | 1.64B | 1.43B | 1.17B | 998M | 810M | 662M |
| INR | 510M | 367M | 239M | 192M | 145M | 177M | 133M | 215M | 193M | 154M |
| INR | — | — | 22.91B | 16.74B | 8.62B | 2.02B | 5.8B | 5.69B | 8.25B | 8.87B |
| INR | 647M | 1.19B | 4.08B | 2.85B | 1.47B | 322M | 1.37B | 1.11B | 1.82B | 1.92B |
| INR | 8.29B | 14.19B | 18.85B | 13.88B | 7.15B | 1.7B | 4.41B | 4.61B | 6.44B | 6.96B |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 5.51B in dividends.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.